glucocorticoid

(redirected from Glucocorticosteroids)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
  • noun

Words related to glucocorticoid

References in periodicals archive ?
While experience in the treatment of this disorder is limited, discontinuation of the drug and glucocorticosteroid therapy is recommended.
1]-antagonist diphenhydramine, the anticholinergic agent atropine, the glucocorticosteroid budesonide, or the bradykinin [B.
Several studies of ICS in young children with asthma have shown similar clinical effects as in older children, including increases in lung function and number of symptom-free days, reduction in symptoms, need for additional medication, caregiver burden, systemic glucocorticosteroid use, and exacerbations.
Glucocorticosteroids and antihistamines, although routinely administered, are not required as urgently as is adrenaline and may be delayed until the patient has been transferred to the stadium medical centre or nearest receiving medical facility.
1) A normal response to the vaccine is usually seen in patients with chronic lung disease, collagen vascular diseases, and even in recipients of moderate doses of glucocorticosteroids.
The Inhaled Steroid Treatment as Regular Therapy (START) trial, sponsored by AstraZeneca, involved 7,165 patients aged 5-66 years with mild persistent asthma of less than 2 years' duration and no previous regular treatment with glucocorticosteroids.
Testing for stimulants, masking agents, glucocorticosteroids and insulin will be run on a mass spectrometry solution provided by AB SCIEX, a global leader in life science analytical technologies.
According to the Gina Guideline, (1) sodium chromoglycate and nedocromil sodium have a limited role in the long-term management of asthma, having weak anti-inflammatory effects and being less active than even low-dose inhaled glucocorticosteroids.
Inhaled glucocorticosteroids are currently the most effective anti-inflammatory medication for the control of persistent asthma.
CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that it has been granted a United States patent (# 7,335,371) entitled "Combinations for the treatment of inflammatory disorders" with broad composition of matter and method of use claims covering combinations of tricyclic antidepressants (TCA) and glucocorticosteroids.
Until recently there was no adequate treatment to address the circadian rhythm of morning stiffness, since administration of glucocorticosteroids in the early hours of the morning during the night is not a practical alternative.
We have demonstrated that the CRx-191 class of tricyclics and glucocorticosteroids are safe and effective in multiple experimental and preclinical models of inflammation, including the Hu-SCID model of psoriasis.
The acute attack can be very easily managed by using non-steroidal anti-inflammatory drugs (NSAIDs), colchicine or glucocorticosteroids, followed up by lifestyle modification and, if appropriate, urate-lowering therapy (ULT).